Chengdu Leading: Currently, most of the company's independently developed new drug projects are in different stages before clinical development, with a lot of uncertainty.

Chengdu Xindao announcement: The closing price of the company's stock has deviated by 30% for three consecutive trading days, which is considered abnormal stock trading volatility. Currently, the company's self-developed new drug projects are mostly in different stages of preclinical development, with a high level of uncertainty in their development. The possibility of future external transfer is highly uncertain.